Breast Cancer
News
Final follow-up of BCIRG-006 shows important cardiac safety differences
An adjuvant trastuzumab-based, nonanthracycline regimen for early HER2-positive breast cancer offers important cardiac safety benefits over the...
News
DNA-mutating enzyme is implicated in tamoxifen resistance
Key clinical point: A high level of APOBEC3B expression in estrogen receptor–positive breast cancer is a marker for tamoxifen resistance. Major...
News
Can aspirin prevent breast cancer?
Aspirin use protects against a known intermediate biomarker of breast cancer risk in a dose-dependent fashion.
Conference Coverage
VIDEO: Dr. Hope S. Rugo discusses immunotherapy, neoadjuvant treatment highlights
Dr. Hope S. Rugo shared her insights on breast cancer research presented at the San Antonio Breast Cancer Symposium.
Video
VIDEO: Dr. William Gradishar says tools to define patients for targeted therapy are on the horizon
News
Ovarian suppression during breast cancer chemotherapy helped preserve long-term function
Key clinical point: Ovarian suppression with triptorelin, a luteinizing hormone-releasing hormone analogue, helped stop chemotherapy from inducing...
Conference Coverage
T-DM1 trial points way to de-escalation of breast cancer therapy
Key clinical point: T-DM1 as neoadjuvant monotherapy enables selected breast cancer patients to avoid neoadjuvant chemotherapy and/or endocrine...
Conference Coverage
ESR1 mutations linked with poorer survival from ER-positive breast cancer
Key clinical point: Women with estrogen receptor–positive advanced breast cancer who have an ESR1 mutation are at increased risk for death. Major...
News
Cancer incidence higher in men, blacks
Conference Coverage
Neratinib shows consistent breast cancer benefit at 3 years
Key clinical point: The significant benefit of delayed adjuvant neratinib following chemotherapy and trastuzumab remains unabated at 3 years’...
Conference Coverage
TH3RESA: T-DM1 prolongs survival in heavily pretreated HER2-positive breast cancer
Key clinical point: T-DM1 is safe and efficacious for treating heavily pretreated HER2-positive breast cancer. Major finding: The median overall...